The Wall Street Journal reports that GlaxoSmithKline is seeking direction from healthcare officials in France, Italy, Spain, and the UK on what drugs under development at Glaxo should be pursued. The pharma company hopes that this will give rise to more drugs that the healthcare systems will buy. A blog post from the WSJ highlights this problem: UK health advisors decided that Glaxo's new breast cancer drug, Tyverb (Tykerb in the US), isn't effective enough for to warrant its £20,000 per year price tag.
Drug of Choice
Jul 07, 2008